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Abstract: Over the last decade interest has been shown in people with symptomatic lung disease
who have features both of COPD and asthma. In this review we examine how COPD and asthma
are defined and examine clinical characteristics of people defined by researchers as having asthma-
COPD overlap (ACO). We look at pathological and physiological features along with symptoms and
consider the impact of each diagnosis upon therapeutic management. We highlight challenges in
the diagnosis and management of airway disease and the various phenotypes that could be part of
ACO, in so doing suggesting ways for the clinician to manage patients with features of both asthma
and COPD.
Keywords: COPD; asthma; asthma–COPD overlap; respiratory pathophysiology; bronchodilator re-
versibility
1. Introduction
Chronic obstructive pulmonary disease (COPD) is now recognised to be a major cause
of ill health, increased health care expenditure and premature mortality internationally [1].
The current definition of COPD advocated by the Global initiative for Obstructive Lung
Disease (GOLD) highlights the importance of persistent airflow obstruction as a defining
characteristic of this condition [2]. Clinically this presents a simple decision. Airflow
obstruction is either present or it is not when the patient performs a technically satisfactory
spirogram. However, the underlying biology of this apparently simple proposition is
more complex.
Longitudinal studies measuring lung function prospectively and cross sectionally
over time [3–5] have shown that both the FEV1 and FVC decrease with age and this is ac-
celerated when people smoke tobacco or are exposed to other noxious inhaled insults [4–6].
Moreover, it is now clear that early life events impact significantly on lung growth and
subsequent decline, resulting in a range of trajectories which the patient may follow up to
the point where a diagnosis of COPD is confirmed by spirometry [7]. Traditionally, airflow
obstruction is defined by the ratio of the FEV1 to FVC with a value of 0.7 or less signifying
that obstructed airflow is present. This simple measurement identifies the presence of
emphysema on CT scanning [8] and people at risk of accelerated lung function loss, at least
in the earlier stages of COPD [9]. However, this ratio decreases with age and apparently
healthy elderly people can be classified as having COPD based on this measurement [10].
This has led physiologists to propose that the lower limit of normal should be used to
identify people where the ratio is below that expected by age [11]. This classifies people
rather differently with more young people and fewer elderly ones being considered to have
airflow obstruction. In practice, this changes relatively little at least in terms of the results
of clinical trials [12] and there are now data suggesting that the fixed ratio of FEV1/FVC of
0.7 is the best predictor of subsequent ill health [13].
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If it has proven difficult to define airflow obstruction, it has been even harder to decide
what the term ‘persistent’ means. This term could imply that obstruction did not resolve
when measured over time, but whether this could include significant improvements
in lung function that were still below the normal predicted value, as is seen in some
patients with chronic asthma, was not clear. These differences in interpretation were
soon recognised as having therapeutic significance. In the 1990s an important paper from
the Netherlands suggested that inhaled corticosteroids (ICS) could produce significant
improvements in symptoms and lung function in COPD patients [14]. Subsequently
these data were challenged, especially by physicians in the UK, who argued that the
improvements seen were due to the inclusion of patients who would normally be diagnosed
as having bronchial asthma. This led to an intense debate about how to best define
bronchodilator reversibility in order to separate COPD from asthma. In Europe, a very
tight definition of irreversible disease was proposed which precluded almost any lung
function change after exposure to an inhaled bronchodilator [15]. This created a ‘Catch 22’
situation where any patient where lung function improved with treatment could not have
COPD because treatment had improved their lung function! Such a tight definition is not
used today but illustrates evolution over time.
As a result, rather than consider in more detail what bronchodilator reversibility might
signify in a patient with structural lung damage due to cigarette (or any other relevant)
exposure, the tendency has been to assign patients to mutually exclusive silos—either
COPD or asthma. Clinicians have always realised that this is an oversimplification and
that some typical COPD patients would show larger than expected benefit from treatment
of various types. What has been less clear is whether this behaviour represents a variation
within an established diagnosis or is a discrete condition which consistently behaves
differently from ‘true’ asthma or COPD.
Over the last decade there has been renewed interest in the idea of an asthma–COPD
overlap (ACO) state in part driven by the desire of the pharmaceutical industry to identify
a subset of COPD patients who might respond better to the existing anti-inflammatory
treatments and to explain why some asthmatic patients did not improve to the degree
anticipated when given them. The most cogent rational academic exploration of this idea
came from Gibson et al. in 2009 [16]. Subsequently there have been many publications
reporting data in patients believed to be exhibiting ACO and suggestions have been made
about how best to operationalise this concept [17–19]. In this review we will consider what
has been proposed and outline our reasons for believing that ACO is not a helpful way to
understand the variation seen in the way that disease develops in patients with asthma
or COPD.
2. Defining ACO
A key issue limiting the usefulness of the ACO concept is the lack of a consistent
definition. This not only hinders academic study but also confuses the clinician. This
problem is not restricted to ACO but has bedeviled the field of ‘airways disease’ for the last
60 years. Indeed, the portmanteau term ‘airways disease’ to describe asthma, COPD and
related conditions is itself unsatisfactory as it fails to account for airflow obstruction due to
emphysema. Clearly if we have issues defining asthma and COPD, it is going to be hard to
identify overlaps between them.
As has been noted before, defining both asthma and COPD is like love—everyone
knows what it is when it happens, but it is hard to explain to other people. By the 1980s
advances in pulmonary pathology and physiology meant that definitions based only on
symptoms such as chronic bronchitis were superseded by approaches using structural
and/or lung function criteria. The CIBA symposium in 1959, perhaps the most famous of
the meetings which attempted to re-define these conditions, proposed definitions based on
variability in lung function for asthma, the presence of enlarged airspaces due to tissue loss
for emphysema and symptoms of chronic cough [20]. Helpful as these definitions were
in providing a focus for further study, they contained a fundamental weakness, namely
Diagnostics 2021, 11, 1189 3 of 20
that each relied on a different domain—physiology, pathology or symptomatology—to
characterise the disease, building in the study of overlap states from the outset.
In the 1970s and 1980s, attention was paid to whether chronic bronchitis or physiology,
in the form of the FEV1, identified discrete natural histories of disease and whether this
differed from that seen with patients diagnosed in life with emphysema. The famous longi-
tudinal study of British postal workers led by Charles Fletcher provided the unexpected
answer that it was lung function that identified individuals whose lung disease progressed
with smoking, rather than the symptoms of bronchitis [21]. Thereafter symptoms were
seen to be secondary to lung pathology identified by abnormal lung function rather than
identifying a discrete condition. While this is likely to be true, the importance of symptoms
like mucous hypersecretion as a marker for respiratory infection and exacerbation [22] and
lung disease in the earliest phases of COPD [23] has been neglected until relatively recently.
The overlap between emphysema and bronchitis (clinically defined) seemed to have
an international dimension with workers in the USA reporting most of their patients with
chronic airflow obstruction as having emphysema (based on CXR appearances) while in
Britain similar patients were defined as being bronchitic [24]. Eventually these semantic
problems were resolved, but there was still a belief that patients with emphysema without
bronchitis maintained normal arterial blood gas tensions while those reporting bronchitis
were more likely be hypoxaemic [25]. Again, subsequent pathology studies showed that
emphysema could be associated with hypoxaemia [26]. With hindsight it is likely that some
of the ‘blue and bloated’ patients had undetected bronchiectasis and/or left ventricular
dysfunction, but this illustrates the way in which ideas about airflow obstructive disorders
has been refracted through the tools available for their study rather than any intellectual
limitation of those leading the investigations.
The contrast between asthma and bronchitis was not immune from the debate be-
tween ‘lumpers and splitters’. Unlike the British who felt that chronic bronchitis was a
discrete disorder of prognostic significance, the Dutch group in Groningen led by Dick
Orie advocated the concept of chronic non-specific lung disease which recognised the
heterogeneous nature of conditions others would describe as bronchitis, emphysema or
asthma, and grouped them together [27]. In this approach we have the origin of the concept
we now consider as ACO and, as noted already, it received considerable push back when
the results of their clinical trial of inhaled corticosteroids was first published [14]. However,
the conceptual framework developed in the Netherlands was taken up by Gordon Snider
in Boston and led to his visual representation of COPD in a non-proportional Venn diagram
which was adopted by the American Thoracic Society in its original Standards of Care
for COPD document [28]. Thus, a potential for ACO was recognized, but its nature was
not clarified.
Longitudinal studies in the Netherlands and New Zealand in young people who have
the clinical and physiological characteristics of asthma have shown how over time they
can develop fixed airflow obstruction which is often diagnosed as being COPD [29,30].
Whether these people have the same pattern of structural damage seen in typical smoking
induced COPD is unclear as is their response to therapy. By contrast, much less information
is available about whether people with typical COPD go on to develop disease features
more typical of chronic asthma.
Although interest in this topic subsequently declined, the 2009 article by Gibson et al.
reignited old uncertainties about whether a discrete phenotype of patients with features
of both asthma and COPD existed [16]. These authors approached this from an asthmatic
perspective and placed significant emphasis on the role of the bronchodilator response in
identifying these patients, as well as emphasising the increased sputum neutrophilia seen
in their ACO subjects compared with asthmatics and healthy older adults. Coming at a
time of concerns about the risk of pneumonia developing in COPD patients treated with
ICS, this approach offered a way of identifying a subgroup for which the benefit of ICS
treatment was easier to justify.
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In response to these concerns, the Global Initiative in Asthma (GINA) and Global
Initiative in Obstructive Lung Disease (GOLD) produced a joint consensus document
highlighting practical approaches to the management of ACO [31]. Subsequently the report
of workshops convened by the ATS and ERS were published [19,32]. The GOLD/GINA
approach was not to offer a specific set of criteria on which a diagnosis of ACO was based
but to suggest that ACO could be considered when features usually considered typical
of asthma or COPD were present in the same patient [31]. This group offered a series of
choices to the clinician about clinical and laboratory features they felt were important,
and more detail can be found on the respective websites. There was no attempt to weight
the features for their relative importance, a task sensibly left to the individual clinician to
decide, from what is basically advice on what to consider in managing patients presenting
with atypical clinical findings. However, this level of individual decision makes it hard
to draw conclusions about the nature and management of this condition and assumes
that treatment approaches valid for the individual diseases are as effective in someone
exhibiting these ‘overlap’ findings.
By contrast, the ATS workshop considered a wider range of issues and raised a series
of research questions which needed to be addressed before the nature of ACO could be
considered finalised [32]. The European consensus group reviewed the entry criteria
used in a range of clinical trials of asthma and COPD and developed a series of major
and minor diagnostic criteria summarised in Table 1. This group provided the clearest
operational definition of ACO but, to date, this has not been widely accepted, with other
groups adapting it to local perceptions of what the key features of ACO might be. The
resulting plethora of reported definitions is summarised in the helpful review of Cazzola
and Rogliani [33]. It is no surprise in this setting that the type of patients included in what
are mainly observational studies appear to be rather different in their nature, illustrated by
Barczyk et al. [34].
Table 1. A Consensus Definition of ACO proposed from an ERS Sponsored Round-table Discussion
[19]. Diagnosis requires the presence of all 3 major criteria plus 1 minor criteria. LLN = lower limit of
normal, BDR = bronchodilator reversibility.
Major Criteria Minor Criteria
• Persistent airflow limitation
(post-bronchodilator FEV1/FVC <0.70 or
LLN) in individuals 40 years of age or
older; LLN is preferred
• At least 10 pack-years of tobacco smoking
or equivalent indoor or outdoor air
pollution exposure (e.g., biomass)
• Documented history of asthma before 40
years of age or BDR of >400 mL in FEV1
• Documented history of atopy or allergic
rhinitis
• BDR of FEV1 ≥200 mL and 12% from
baseline values on 2 or more visits
• Peripheral blood eosinophil count of
≥300 cells/µL
These problems in definition raise several concerns about the utility of the term ACO
as an aid to both academic and clinical understanding of people with objectively defined
airflow obstruction. In the following sections we will examine what evidence we have for
a discrete overlap of pulmonary pathology between asthma and COPD, whether patients
meeting the definition of ACO behave differently from others not diagnosed in this way and
whether objective physiological tests which are often the main driver of an ACO diagnosis
can be relied on to distinguish these patients from others with chronic airflow obstruction.
3. A Pathology of ACO?
There is a dearth of evidence for a discrete pathology occurring in ACO patients. This
reflects the lack of a clear definition discussed above and the fragmented nature of the data
about structural and immunological features of those who do meet whatever definition is
considered appropriate. The issue is not just whether the pathologies typical of asthma
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or COPD co-exist in the same person, but in how many people such features are present
without them exhibiting the defining conditions of the overlap state.
In most cases it is accepted that a prior clinical diagnosis of asthma indicates the
continuing presence of that condition. However, this is not necessarily the case. Often
the diagnosis is not confirmed by any objective measurement and, in the case of the
overlap between asthma and obesity, an asthma diagnosis is often made in patients without
any evidence of enhanced airway responsiveness or spontaneous fluctuation in lung
function [35]. The clearest evidence for a common set of pathological characteristics in
asthmatics has come from biopsy studies largely conducted in milder disease and autopsy
data in the relatively few people who die from the disease. In most cases there are features
of Th-2 inflammatory changes, increased numbers of eosinophils in the tissue and airway
lumen and, as the disease worsens more neutrophils accumulate. A striking finding is
the increase in bulk of the airway smooth muscle which helps explain several of the
physiological features of the disease [36–38].
For many years there was a consensus based on chest X-ray studies that emphysema
only rarely occurs in asthmatic patients but was a frequent finding in those presenting
with COPD. It is now clear that in most COPD patients the loss of the small airways
precedes the development of emphysema which becomes a more prominent feature as
lung function loss worsens [39,40]. The advent of quantitative CT scanning has allowed the
relationship between structure and function to be explored in life. One of the best studies
is that of Hartley et al. who studied 171 asthmatics, 81 COPD patients and 49 healthy
subjects [41]. Patients met standardised diagnostic criteria and were not classified as being
ACO or non-ACO in nature. These workers found that airway wall thickness increased
as FEV1 decreased in asthmatics, but the degree of air trapping, a measure of pulmonary
hyperinflation, was the main driver of a low FEV1 in COPD patients. The degree of
emphysema contributed to the decreased FEV1 in COPD patients but was infrequent in
patients with asthma. Thus, different pathological changes contribute to the impaired
physiology, but airways disease plays a role either directly or indirectly in both asthma
and COPD.
These pathological issues have been more directly addressed by a Japanese group
who report 3D CT imaging in COPD patients with and without a diagnosis of ACO based
on the presence of a bronchodilator response and matched for their smoking history [42].
In this study an FEV1 change of more than 12% baseline and 200mL after an unspecified
bronchodilator or 4 weeks of anti-inflammatory treatment together with variable symptoms
were used to define ACO. Patients exhibiting a positive response had thicker proximal
airways and less evidence of emphysema than those who did not. However, the mean
FEV1 in this study was relatively high at 70% predicted, so extrapolation to more severe
COPD should be done with caution.
Direct study of the nature of airway inflammation in ACO subjects should help resolve
matters. One of the few studies to report data on this topic came from a group in Basel
who systematically collected biopsies from 129 COPD patients without features of asthma,
19 smoking asthmatics and 18 COPD patients with ACO, all of whom were undergoing
diagnostic bronchoscopy and biopsy procedures. They defined ACO using a modified ERS
consensus definition [43], but unlike other studies the ACO group did not show greater
reversibility to salbutamol that the non-ACO COPD patients. The ACO patients had higher
exhaled breath nitric oxide concentrations, more blood eosinophils and significantly better
lung function than the COPD control group. These differences in disease severity make it
difficult to interpret the greater degree of basement membrane thickening seen in the ACO
patients compared with the smoking asthmatics. As the authors comment, their data is
preliminary and other focused studies will be needed to address the question of what kind
of pathological changes occur in what patients.
An alternative approach to establishing overlap would be to look for differences in
biomarkers of tissue inflammation between ACO and non-ACO COPD patients. This
would be a very helpful strategy if the biomarkers concerned were both specific and
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sensitive in distinguishing asthma from COPD. Many inflammatory biomarkers have been
linked to asthma with fractional exhaled breath nitric oxide (FeNO), being widely used as
a marker of Th-2 inflammation. Unfortunately, the inflammatory process and its attendant
biomarkers change as the clinical presentation of asthma evolves, with a more neutrophilic,
less eosinophilic profile being seen in severe asthma, especially among patients who are
relatively resistant to systemic corticosteroid treatment [44]. Blood eosinophilia is seen as a
marker of airway eosinophilia, although studies where these variables have been directly
compared suggest that this relationship is relatively weak [45] and there is little agreement
about what constitutes eosinophilia and how best to express the data. Unsurprisingly, a
raised peripheral blood eosinophil count is not required in the diagnosis of asthma [46].
Nonetheless, the peripheral blood eosinophil count does predict the response to biological
treatments in severe asthma [47] and in general population samples of COPD sufferers,
those with an eosinophil count as high as 350–600 cells /µL have an increased risk of
hospitalisation [48].
Attempts to use these variables to separate ACO from COPD patients who do not
meet the clinical criteria for this condition have generated conflicting results. Li et al.
found that in 48 patients (42% with a history of smoking and 50% taking ICS) that an
FeNO >31.5 ppb identified patients with ACO who smoked with a sensitivity of 70% and
a specificity of 90% [49]. However, both the reproducibility of these threshold values
and their predictive power need to be replicated in other cohorts. Nonetheless, there is
a growing sense that patients who have a history of asthma before the age of 40 behave
differently to those whose smoking related COPD develops later in life. Data from Spain
suggests that the airway responsiveness is greater, peripheral blood eosinophil count
is higher and serum IgE levels are higher in COPD patients with a prior diagnosis of
asthma [50]. Further work on well characterised cohorts preferably with appropriate CT
imaging should help clarify these relationships. However, the largest comparative cohort
study to date, NOVELTY, found no difference in blood eosinophil counts between the
asthma, COPD and asthma-COPD overlap groups that they recruited [51], suggesting that
blood eosinophils are not useful discriminants in routine clinical practice in identifying
what physicians felt constituted ACO.
In many ways the most powerful argument for the existence of an overlap state
between asthma and COPD comes from genetics. By combining data from several patho-
logical studies in asthma and COPD, Christenson et al. found that genes associated with a
Th2 phenotype in asthmatics were also expressed in patients with COPD and that blood
eosinophil counts and airway responsiveness were increased when this was the case [51].
They argue that these genes might be involved in the earlier stages of the development of
COPD. However, it is important to recognise that the pathological changes associated with
COPD differed from those seen with asthma, with the exception of the eosinophil numbers.
Clearly these findings also merit replication in patients meeting any of the current ACO
definitions.
4. The Clinical Significance of ACO
It could be argued that it is not important whether or not there is a clear definition
of ACO if clinicians can identify a group of patients who should be managed differently.
This approach runs the risk of committing the Procrustean crime of making the facts fit the
prejudice of the observer—in this case that ACO must exist.
In Table 2 [52–61] we summarise some of the many studies which have looked at
the clinical characteristics of ACO (defined in a variety of ways) in clinical populations
which vary by country and care setting. The reported prevalence of the condition varies as
does the sample size studied, ranging from 1.5% to 27.4% of populations with asthma or
COPD. As noted by Spanish workers, the very strict definition of substantial bronchodilator
reversibility change excludes so many patients that the definition had to be relaxed to
allow them to identify anyone with ACO [54]. This approach feels like a very uncertain
way of defining a disease as the higher threshold had originally been suggested as a way
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of avoiding random variation in a positive BDR (see below). There is an impression that
patients identified as having ACO are somewhat younger, are more symptomatic and
more likely to report exacerbations than COPD patients not identified in this way. This
is supported by several of the review articles which have summarised the findings in
these and/or other data sets [16–18,33,62]. Two further studies are worthy of note. In a
validation of the ERS symptom score, Nelsen et al. found that most of the symptoms in the
battery worked as well for COPD as for ACO, i.e., clinically the patients were very similar.
However, wheeze seemed to differ and was not a reproducible symptom, suggesting that
reliance on this complaint, at least in COPD patients, could be misleading [63]. A different
approach was used by Pascoe who reported a mathematical analysis of a health symptom
questionnaire in a large population of patients with obstructive lung disease. The resulting
model was accurate in distinguishing asthma and COPD but the authors suggest that
patients not falling into these groups are very heterogeneous and hard to classify [64]. This
heterogeneity is emphasised by the results of the NOVELTY study [52]. Here over 11,000
patients entered an observational study based on their doctor diagnosed asthma, COPD
or ACO. There was substantial heterogeneity across the diagnostic groups and physician
determined disease severity classes showing that, in the ‘real world’ diagnostic groupings
are not rigidly applied.
Table 2. Selected studies reporting clinical features of people with ACO.
Study Definition of ACO Main Findings
Reddel et al. [52] Physician diagnosis of asthma, COPD or both
12.4% asthma and COPD (ACO)
More likely to smoke, higher blood neutrophil
count, more breathless and poorer health status
compared with asthma
Earlier diagnosis, more upper airway disease
compared with COPD
Bronchodilator responsiveness and FeNO
similar across groups
Morgan et al. [53]
Features of both:
COPD—post-bd FEV1/FVC below LLN and
Asthma—self report physician asthma diagnosis, use
of asthma medication last year or wheezing last year
Prevalence of ACO 3.8% in LMIC residents
People with ACO had more biomass fuel
exposure, higher smoking and lower
educational attainment
Worse AFO than asthma or COPD groups
Toledo-Pons et al. [54]
Three groups:
Diagnosed with asthma and COPD
(smoking asthmatic)
COPD and bronchial hyperresponsiveness (FEV1
increase >400 mL and 15%) (COPD high
bronchial response)
COPD and eosinophilia (eosinophils >300cells/µL)
(COPD eosinophilia)
27.4% fulfilled one or more criteria for ACO
13.8% smoking asthmatic, 12.1% COPD with
eosinophilia and 1.5% COPD with high
bronchodilator response
Smoking asthmatics were younger, more likely
female and more atopic
Singh A et al. [55]
COPD—post-bronchodilator FEV1/FVC <0.7
Asthma—>200 mL and >12% improvement in FEV1
with bronchodilator
ACO—both present
Prevalence of ACO 4.6% in firefighters
Eosinophil count >300 cells/µL more common
in ACO
More likely to have accelerated decline in FEV1
Cosentino et al. [56]
ACO; either:
history of asthma or hay fever, FEV1/FVC <0.7,
>200 mL and >12% improvement in FEV1 with
bronchodilator and less than 15% emphysema
on CT, or
FEV1/FVC <0.7, >400 mL and >15% improvement in
FEV1 with bronchodilator and less than 15%
emphysema on CT and less than 15% emphysema on
CT regardless of history of asthma or hay fever
Compared to subjects with COPD and
emphysema ACO subjects were younger, more
likely African-American, higher BMI and more
likely to still smoke
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Table 2. Cont.
Study Definition of ACO Main Findings
Krishnan et al. [57]
ACO defined as >40 years old, current or former
smoker, FEV1/FVC <0.7 and >200 mL and >12%
improvement in FEV1 with bronchodilator
Prevalence of ACO of 18.2%
More common in people diagnosed with both
asthma and COPD
Younger and higher BMI compared with
COPD cohort
More likely to smoke and less rhinitis than
asthma cohort
Izbicki et al. [58]
COPD was defined as FEV1 <80% predicted and
FEV1/FVC <0.7. ACO was defined as this plus
>200 mL and >12% improvement in FEV1 with
bronchodilator
No differences seen compared with the COPD




ACO defined as COPD patients reporting a previous
diagnosis of asthma
Classified as ACO2 if had 2 major or 1 major & 2
minor criteria:
Major criteria were improvement in FEV1 >400 mL
and >15% with bronchodilator, sputum eosinophilia or
a previous diagnosis of asthma before the age of
40 years
Minor criteria were increased total serum
immunoglobulin E, previous history of atopy or FEV1
>200 mL and >12% on two or more occasions
Prevalence of ACO of 15.9%
Two thirds did not fulfil ACO2 criteria
ACO subjects were more likely to be female,
had more exacerbations, had better lung
function and higher blood eosinophilia
Llanos et al. [60]
40 years old or greater with at least 1 asthma and 1
COPD characteristic:
Asthma characteristic—even given a physician
diagnosis of asthma or had an ‘asthma attack’ in the
previous year
COPD characteristic—post-bd FEV1/FVC <0.7 and
ever told they had emphysema or chronic bronchitis
by a physician
ACO subjects had poorer lung function than
those with asthma or COPD, higher eosinophil
counts than those with asthma or COPD and
had more ‘asthma attacks’ than the
asthma group
Baarnes et al. [61] At least 1 previous hospitalisation for asthma and 1for COPD
Subjects with ACO were older, more likely to
smoke, had lower educational attainment and
took less regular exercise
So far, data have largely focused on the overlap of COPD and asthma, i.e., in patients
who look like they have COPD, how many have some features that are atypical and would
fit better with a diagnosis of asthma. There are plentiful data about what happens when a
young person diagnosed with asthma continues with symptoms into adulthood. Work from
the Netherlands, Aberdeen, Australia and New Zealand have shown in patients followed
for up to 45 years that a significant number of asthmatics go on to develop fixed airflow
obstruction which is re-defined as COPD by the clinicians managing them [29,30,65–67]. In
a recent report of children followed to age 45, a diagnosis of ACO based on the presence of
airflow obstruction and a history of previous asthma irrespective of smoking history was
made in an estimated 3% of the population and, like COPD without an asthma diagnosis,
was especially likely to do so in those with the worst lung function at the age of 7 years [65].
These data provide further support for the early origins of COPD in a significant number
of patients but ACO described here represents a different entity from the COPD with
asthmatic features that has fueled much of the ACO debate [68]. It is now clear that
tobacco smoking decreases the effectiveness of inhaled corticosteroid treatment in both
asthma [69] and COPD [70], further complicating the distinction between COPD with
asthmatic features and asthma with features of COPD in longitudinal studies like that of
Bui et al. [65].
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5. The Physiology of ACO
Thus far, physiological measurements made in ACO patients have been largely con-
fined to spirometry rather than collecting data about lung volumes or gas transfer. Some
studies have reported the results of non-specific bronchial challenge testing with either
inhaled histamine or methacholine as the inhaled agonist [71,72], but most studies restrict
themselves to reporting the results of a single bronchodilator reversibility test (BDR) usu-
ally using inhaled salbutamol as the test drug. The interpretation of this apparently simple
test has proven to be fraught with difficulty, especially in patients with COPD and has been
reviewed in detail on several occasions [73]. As these tests are often crucial in the clinician’s
decision about whether the patient has ACO or COPD, it is important to consider them
in some detail and to highlight why simple assumptions about how to interpret them can
be misleading.
In routine laboratory practice both the measurement of airway hyperresponsiveness
(AHR) and BDR rely on changes in the FEV1, the volume that a subject can expire in
one second during a forced expiration from total lung capacity. Reliable standards exist
for the performance [74] which exploits the development of flow-limitation during the
manoeuvre to reduce between test variation. Nonetheless there is a short term and between
day physiological variation in the FEV1, which means that tests repeated a few minutes
apart can differ by chance by up to 160 mL. Rather surprisingly this between test variability
is not much influenced by the initial FEV1 of the subject, although it is somewhat lower
when the pre-test FEV1 falls below 1.5 L. By contrast the FVC is more effort dependent with
a potential for more between test variation which has meant that it is less often reported
during AHR and BDR tests. This is unfortunate as change in FVC gives more clinically
relevant data about lung volume change in COPD and has been suggested as a better guide
to AHR in asthma [75].
Although considered as being equivalent measurements of airway smooth muscle
responsiveness, AHR and BDR tests are not interchangeable and often say more about
the pathology of the surrounding lung than the medium sized airways where most of the
inhaled stimulant is delivered. In general, AHR testing is used to diagnose asthma with a
series of threshold changes identifying mild to severe degrees of airway irritability. This
approach works well if the initial FEV1 is relatively normal, but as the pre-test FEV1 falls
the same dose of agonist can produce a more dramatic fall in FEV1 due to the altered airway
geometry rather than a greater degree of airway smooth muscle contraction. In this context,
absence of AHR is more informative than its presence, as has been seen when trying
to interpret the diagnosis of asthma in obese subjects [34]. Relatively few groups have
looked at AHR in more severe COPD. When we did, we found that this was a surprisingly
frequent occurrence [76] and accompanied by increases in end-expiratory lung volume,
likely reflecting worsening flow limitation with the agonist drug. Although relevant to why
such patients were more symptomatic and are prone to more exacerbations of COPD, we
were confident that the changes we saw were related to predictable physiological changes
in patients with more severe lung damage due to typical smoking-related COPD, as these
patients had no pointer to a diagnosis of asthma, either currently or in their past. Structural
differences may help explain the observation in mild to moderate COPD that those with
the greatest AHR show the fastest decline in FEV1 over time [77].
The situation around interpreting bronchodilator responsiveness is, if anything, even
more complex. Table 3 summarises some of the main issues that have emerged over several
decades of applying this test in clinical practice. Unlike AHR testing, which examines the
ease with which airway smooth muscle contraction can be induced, BDR testing looks
at the effect of an inhaled drug that promotes airway smooth muscle relaxation (usually
4 puffs of salbutamol) to improve lung function over a short time, commonly 15 min. This
is a satisfying test to conduct in a labile asthmatic patient where the FEV1 can increase by
500 mL or more and often returns to values within the predicted normal range. This form
of acute reversibility is diagnostic of bronchial asthma when it occurs but is not the kind of
change commonly seen in patients diagnosed as having ACO.
Diagnostics 2021, 11, 1189 10 of 20
Table 3. Problems when interpreting bronchodilator responsiveness in people with COPD [73].
Pitfall with Reversibility Testing Reason for the Problem
The bronchodilator drug used
Additional bronchodilation with the
combination of short-acting beta-agonists and
short-acting anti-muscarinics compared to
one bronchodilator
The timing of reversibility testing
Short-acting anti-muscarinics achieve
maximum bronchodilation longer than 15 min
after administration, the timing typically used
for beta-agonist reversibility
The dose of bronchodilator drug
Higher doses of salbutamol (>400 mcg) will
result in further small increases in FEV1
compared with lower doses
The reproducibility of result
The magnitude of reversibility, and
classification of reversibility (positive or
negative), varies significantly between tests
The impact of pre-test FEV1 Individuals with a lower pre-test FEV1 are lesslikely to shown significant reversibility
The clinical implications of reversibility
Reversibility does not predict clinical
symptoms, exacerbations and subsequent
decline in lung function
As with AHR testing, the physiological basis of BDR is more complex than is com-
monly appreciated. Airway smooth muscle (ASM) is widely present throughout the
bronchial tree down to the terminal bronchioles. In health there is a normal spontaneous
variation in the degree of airway smooth muscle activation (ASM tone) which can be
reduced or abolished by bronchodilator drugs; hence the enthusiasm of endurance athletes
to acquire a diagnosis of asthma. This spontaneous fluctuation in ASM tone is exaggerated
in bronchial asthma through a combination of airway inflammation and enhanced ASM
bulk [78] but is preserved in COPD. However, in these patients the baseline airway calibre
is reduced and structural changes can increase the degree to which normal physiological
changes in ASM translate into changes in airflow resistance which is being indirectly as-
sessed by the FEV1. These effects are not as dramatic as is the case in bronchial asthma but
are more than enough to account for the variable bronchodilator responses that charac-
terise many COPD patients. None of this requires there to be any ‘co-existing’ asthmatic
pathology in the lungs of the COPD patient.
These theoretical considerations aside, there are many obstacles to the easy interpreta-
tion of a bronchodilator reversibility test. The protocol adopted will influence the result.
In patients with moderate–very severe airflow obstruction the number of positive tests
rises with the number of bronchodilators given to the patient [79], a fact clinically exploited
in the use of long-acting inhaled dual bronchodilators [80]. There has been an extensive
discussion about how to define a positive result. The simple approach of looking for a large
percentage change from baseline works well if the pre-test FEV1 is relatively preserved,
but a 160 mL increase in FEV1 which is within the spontaneous variability of two FEV1
measurements could be interpreted as 16% reversibility in a patient with a baseline FEV1
of 1 L. This led to the current recommended volume change which must be at least 12%
of the baseline value and exceed 200 mL [81]. This was derived from basic principles and
experience in population studies rather than empirical data from studies of COPD patients
which helps explain its problems in clinical practice. Using a very large absolute difference
of 400 mL between measurements to define a positive test greatly decreases the number
of positive responses, but did not abolish the between visit fluctuation in classification in
those who tested positive initially as shown in Figure 1 from the ECLIPSE study [82].
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where both bronchodilators were administered together [79].
It would be helpful if patients with a positive BDR on one occasion behaved differently
from those who did not but this does not seem to be true, at least in studies where patients
did not have a history of prior asthma. The 4-year UPLIFT trial found no relationship
between health status or exacerbation rate and the initial bronchodilator response [83].
This was confirmed in the ECLIPSE dataset [82]. The ECLIPSE investigators went on
to look at the subset of patients who were consistently positive on testing over 3 years
and compared them to those with consistently negative tests and found no difference in
mortality, hospitalisation or exacerbation rates.
In su ary, classification of individual patients as having an asth a–C P overlap
condition based on a single bronchodilator test is unreliable and influenced by the nature
of the test con cte , the severity of pre-test lung function impairment, the way in which it
is interpreted and between day fluctuations in ASM tone. How much of t e apparent differ-
enc in b haviour at a group level is det rmin d by a greater than nticip ted improvement
in FEV1 after a short-term br nchodilator test remains unc rtain.
. ti li ti
f t i r s s t i tif ti ts s i l t r t ir
treat e t i r er t reflect t e rese ce f a res e al at l a te tial
treat ent approaches have been revie ed before [84]. t present there is no evidence base
co paring treatment efficacy in individuals meeting any of the ACO definitions with those
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with ‘pure’ COPD. Indeed, it seems unlikely that important differences would emerge
in patients selected on the basis of any of the composite definitions currently proposed.
Among COPD patients it is clear that even those who do not exhibit a positive response still
benefit from long-acting inhaled bronchodilator treatment in terms of improved exercise
capacity and reduced degrees of exertional breathlessness [85]. Hence, it would be illogical
to restrict the use of these treatments to those who met the ACO criteria.
The crucial drug class where a clear distinction might be helpful is in the use of anti-
inflammatory drugs. The most studied class has been ICS and here prior belief seems to
trump evidence. For many working in this field it has been an item of faith that inhaled cor-
ticosteroids are ineffective in COPD and hence they need an explanation for the large body
of data that show that ICS, usually combined with a long-acting inhaled bronchodilator,
can improve health status, decrease exacerbation frequency, decrease the rate of decline in
FEV1 and prolong life in a large clinical trial population [86]. The suggestion that positive
results reflect the presence of a ‘hidden’ asthmatic population overlapping with ‘pure’
COPD is not supported by re-analysis of the trial data [87]. However, one characteristic
which is part of some definitions of ACO can properly be considered to be a treatable trait
on which therapeutic choices about ICS use can be based.
As discussed above blood eosinophil counts have been proposed as a way to identify
an ACO subtype of COPD. Airway eosinophilia has been studied in airways disease for
almost 20 years mainly focusing on patients with asthma and reporting induced sputum
data [88]. However, the relationship between induced sputum eosinophil counts and those
in blood is weak in patients diagnosed with COPD [89]. The recognition that COPD patients
in the highest tertile of the normal range of eosinophil counts experienced significantly
fewer exacerbations when treated with ICS+LABA compared with LABA alone changed
perceptions radically [90]. These data were confirmed in other data sets [91,92] as a better
understanding emerged about how best to interpret the threshold where the beneficial
effect of ICS on exacerbation frequency emerged. In general, this was dictated by the a priori
likelihood of an exacerbation occurring and the amount of background bronchodilator
treatment, with patients with a blood eosinophil count and a prior exacerbation history
being likely to benefit from using ICS irrespective of the degree of concomitant therapy [93].
The extent of peripheral blood eosinophilia did not influence any positive effect of ICS
on either FEV1 or health status, but there are retrospective data suggesting that patients
with higher blood eosinophil counts have a reduction in lung function loss over time
when treated with ICS [94]. Rather surprisingly, the same association between blood
eosinophil count and the effect of treatment on exacerbations was seen with a different
agent, roflumilast [95]. Like inhaled corticosteroids [96], this drug decreases the degree
of eosinophilia seen in airway biopsies [97]. Further mechanistic studies explaining these
effects are needed.
The problem for the ACO concept is that the presence of a higher blood eosinophil
count is not related to other proposed features of an ACO diagnosis. The distribution of
blood eosinophils in COPD populations is not different from that seen in healthy patients
without the disease [98], suggesting that the coexistence of a higher count and COPD occurs
by chance rather than due to a specific causal mechanism. As noted already, the blood
eosinophil count in the large observational NOVELTY study was not different between
patients with an ACO diagnosis and those thought to have usual COPD [51], a finding
that held true across the clinician-determined range of disease severity (Figure 3). The
diagnostic classification did have some significance as ACO patients were more likely to
receive ICS treatment in disease perceived to be mild or moderately severe than was the
case if COPD alone was diagnosed. However, a similar percentage of patients with severe
disease received ICS and ICS+LAMA+LABA treatment irrespective of which diagnostic
label was applied.
Diagnostics 2021, 11, 1189 14 of 20




Figure 3. Mean absolute eosinophil count (cells/µL) in 11,243 patients who participated in the NOVELTY study which 
included 5940 with a physician diagnosis of asthma, 3907 with a physician diagnosis of COPD and 1396 with a physician 
diagnosis of asthma and COPD. The physician also assessed disease severity as mild, moderate or severe [51]. 
7. Conclusions 
Doctors select medical labels for a variety of reasons—to explain to patients that their 
problems have a rational basis with predictable outcomes that are amenable to proven 
treatment, to indicate the likely clinical course and prognosis of the condition and finally, 
on some occasions, to conceal their diagnostic uncertainty and allow them freedom to se-
lect treatment that a more restrictive diagnosis would not necessarily allow. It is our view 
that most cases diagnosed as ACO fall into this last category. This is not due to any ill-
intent on the part of the doctor but reflects the multidimensional way in which the diag-
nosis of asthma and COPD have been presented over the years with a lack of clarity about 
which features carry most weight in reaching a diagnostic conclusion and uncertainty 
about how the clinical manifestations of the illness relate to the pathological changes and 
disease mechanisms which cause them. It is now possible using more objective measure-
ments made in life to categorise these processes differently but the ubiquity of both 
asthma and COPD, coupled with the long natural history of both conditions, make imple-
menting this a challenging undertaking. Hence, we are likely to be left with composite 
diagnostic categories which will inform our clinical and academic approach to these con-
ditions. This highlights the need for long-term cohort studies to better understand both 
the real-life trajectories of COPD and asthma over time, and to better identify phenotypes 
of patients who may experience features of COPD and asthma. The question remains in 
this setting—is ACO a useful diagnostic subdivision? As our review of the evidence sug-
gests, we do not believe this is the case. 
At the individual patient level, the lack of agreement about what a doctor might 
mean by the term ACO is a huge drawback. Extrapolating treatment algorithms for this 
condition based on what occurs in its better-defined progenitor conditions is not helpful. 
Reliance on a positive bronchodilator response means that the chance of the diagnosis 
being changed rises with the number of times the test is repeated, even when relatively 
strict definitions of a positive response are applied. Even if the response is positive, it does 
not preclude a useful response to the currently available inhaled therapies. Selection of 
Figure 3. Mean absolute eosinophil count (cells/µL) in 11,243 patients who participated in the NOVELTY study which
included 5940 with a physician diagnosis of asthma, 3907 with a physician diagnosis of COPD and 1396 with a physician
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7. Conclusions
Doctors select medical labels for a variety of reasons—to explain to patients that their
problems have a rational basis with predictable outcomes that are amenable to proven
treatment, to indicate the likely clinical course and prognosis of the condition and finally,
on some occasions, to conceal their diagnostic uncertainty and allow them freedom to select
treatment that a more restrictive diagnosis would not necessarily allow. It is our view that
most cases diagnosed as ACO fall into this last category. This is not due to any ill-intent
on the part of the doctor but reflects the multidimensional way in which the diagnosis of
asthma and COPD have been presented over the years with a lack of clarity about which
features carry most weight in reaching a diagnostic conclusion and uncertainty about how
the clinical manifestations of the illness relate to the pathological changes and disease
mechanisms which cause them. It is now possible using more objective measurements
made in life to categorise these processes differently but the ubiquity of both asthma and
COPD, coupled with the long natural history of both conditions, make implementing
this a challenging undertaking. Hence, we are likely to be left with composite diagnostic
categories which will inform our clinical and academic approach to these conditions. This
highlights the need for long-term cohort studies to better understand both the real-life
trajectories of COPD and asthma over time, and to better identify phenotypes of patients
who may experience features of COPD and asthma. The question remains in this setting—is
ACO a useful diagnostic subdivision? As our review of the evidence suggests, we do not
believe this is the case.
At the individual patient level, the lack of agreement about what a doctor might mean
by the term ACO is a huge drawback. Extrapolating treatment algorithms for this condition
based on what occurs in its better-defined progenitor conditions is not helpful. Reliance on
a positive bronchodilator response means that the chance of the diagnosis being changed
rises with the number of times the test is repeated, even when relatively strict definitions
of a positive response are applied. Even if the response is positive, it oes ot preclude a
useful resp se to the currently avail ble inhaled therapies. Selection of patients based on
relative blood osinophilia has a better evidenc base, at least for exacerbation prev ntion
with some anti-inflammatory t atments. However, these ben ficial eff cts are l nked t
the higher blood eosinophil count (whi h itself shows modest between day varia )
rather than the other features of ACO and appear to be distributed across the general
population rather than confined to a particular subset of patients with airways disease. In
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larger population studies, subjects identified as having ACO report more exacerbations
than those with COPD alone. This may reflect the nature of their COPD pathology which
increases their apparent AHR and leads to more between day fluctuation in airway calibre
for reasons other than abnormal airway smooth muscle function.
Several approaches have been proposed to deal with these issues of classification. In a
thoughtful article Wise and Putcha suggest four different ‘phenotypes’ of ACO (Table 4)
which best explain associations between persistent airflow obstruction and asthma [99].
Like the other proposed definitions of ACO, there is a need for longitudinal data to prospec-
tively determine the stability of the diagnostic groups and their subsequent outcomes.
A more attractive approach is based on the approach of Agusti et al. who emphasise
the treatable traits which may be present in an individual patient, where a high blood
eosinophil count is seen as a biomarker of the ability of ICS to prevent exacerbations
rather than a defining characteristic of a specific disease [100]. How widely this return to
Orie’s chronic non-specific lung disease will be accepted remains to be seen. Like others
who have reviewed this issue [17–19,33] we tend to the view that it is better to ascribe a
dominant likely pathology and describe the individual features that need most attention
(e.g., exertional dyspnoea, frequent exacerbations, weight issues, social impacts) rather
than creating a separate disease category that follows a different treatment schedule of
uncertain relevance to the patient’s needs.
Table 4. A suggestion for different pathways to ACO presented as 4 different ‘phenotypes’ of ACO
described by Putcha and Wise [99].
Phenotype of ACO Clinical and Biological Features
Smokers with airflow obstruction and
eosinophilic inflammation
Exacerbations driven by eosinophilic inflammation
Better lung function, less emphysema, less
disease progression
Better response to oral and inhaled corticosteroids
Higher level of atopy
Resistant asthmatic
Asthmatics less responsive to corticosteroids
Higher level of irreversible airflow obstruction
Neutrophil dominated airway inflammation and
exacerbations are more common
Elderly asthmatic with irreversible
airflow obstruction
Long-standing asthma and irreversible
airflow obstruction
Neutrophil dominated airway inflammation
Loss of lung elastic recoil and more hyperinflation
Childhood asthmatic who smokes and
has developed COPD
Asthma as child or young adult but
long-term smoking
Higher number of pack years (more likely to have
>20 pack years)
High symptom burden and healthcare utilisation
Thus, the conclusion reached by the person who has thought most about this topic
and advocated the renaissance of the term ACO in 2009, when they revisited this topic in
2015 [62], seems the most appropriate summary of the case against ACO independently
of COPD:
“A precise and useful definition of asthma–COPD overlap has not been possible, and
the condition itself appears to compromise several different sub-phenotypes. It is proposed
that addressing disease components via a multidimensional approach to assessment and
management of obstructive airway diseases will be useful to manage the heterogeneity of
these conditions.”
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